BENSALEM, Pa., Aug. 5, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Fiserv, Inc. ("Fiserv" or the "Company") (NYSE: FI). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN FISERV, INC. (FI), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE SEPTEMBER 22, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smi ...

Core Viewpoint - Novo Nordisk (NVO.US) faces a decline of over 2% in stock price to $47.64 due to a downward revision of its annual revenue and operating profit growth expectations, linked to challenges in the GLP-1 market [1] Group 1: Legal Issues - A group of shareholders has filed a proposed class action lawsuit against Novo Nordisk in federal court in New Jersey, seeking compensation for alleged securities fraud from May 7 to July 28, 2025 [1] - The plaintiffs accuse Novo Nordisk of making overly optimistic statements and disseminating false and misleading information, exaggerating its growth potential while concealing significant adverse facts [1] - The lawsuit claims that the downward revision of performance guidance led to a sharp decline in stock price, resulting in shareholder losses [1]

Core Viewpoint - Novo Nordisk (NVO.US) faces a decline of over 2% in stock price to $47.64 due to a downward revision of its annual revenue and operating profit growth expectations, citing challenges in the GLP-1 market as the reason for the adjustment [1] Group 1: Legal Issues - A group of shareholders has filed a proposed class action lawsuit against Novo Nordisk in a federal court in New Jersey, seeking compensation for losses allegedly caused by securities fraud between May 7, 2025, and July 28, 2025 [1] - The plaintiffs accuse Novo Nordisk of making overly optimistic statements and disseminating false and misleading information, exaggerating its growth potential while concealing significant adverse facts [1] - The lawsuit claims that the downward revision of performance guidance led to a sharp decline in stock price, resulting in shareholder losses [1]

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation and certain officers for alleged violations of federal securities laws during the Class Period from January 29, 2024, to March 11, 2025, seeking damages for affected investors [1][2]. Company Overview - iRobot designs, builds, and sells robots and home innovation products globally, primarily known for its Roomba robot vacuum cleaner [4]. - The company has faced declining business performance over the past decade, with market share dropping from 64% in 2016 to 46% in 2020 due to competition from lower-priced alternatives [5]. Recent Developments - In August 2022, iRobot entered a merger agreement with Amazon for $61 per share, valued at approximately $1.7 billion, but the deal was terminated in January 2024 due to regulatory concerns [6]. - Following the termination, iRobot announced significant layoffs, cutting approximately 350 employees, or 31% of its workforce, and a restructuring plan aimed at stabilizing the company [7]. Financial Performance - iRobot reported a loss of $2.06 per share on revenue of $172 million for Q4 2024, marking a 44% year-over-year decline [9]. - The company expressed substantial doubt about its ability to continue as a going concern for at least 12 months following the issuance of its 2024 financial statements [9]. Market Reaction - Following the negative financial results and outlook, iRobot's stock price fell by $3.255 per share, or 51.58%, over two trading sessions [10]. - Despite a short squeeze in May 2025 due to delayed U.S. tariffs on EU imports, analysts noted that iRobot's underlying financial fundamentals remained concerning, with deteriorating cash reserves and operational stress [11].

Core Viewpoint - A class action securities lawsuit has been filed against Petco Health and Wellness Company, Inc. for alleged securities fraud affecting investors between January 14, 2021, and June 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Petco's pandemic-related business advantages were not sustainable and that its business model, which focuses on premium pet food, was overstated [2]. - It is alleged that the defendants minimized the true extent of the issues facing Petco, including the necessary changes to address these issues and the potential negative impacts on comparable sales [2]. - The lawsuit asserts that the defendants misrepresented Petco's ability to achieve sustainable and profitable growth, leading to materially false and misleading public statements [2]. Group 2: Next Steps for Investors - Investors who experienced losses in Petco during the specified timeframe have until August 29, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be eligible for compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Novo Nordisk (NVO.US) is facing a shareholder lawsuit due to a downward revision of its full-year revenue and operating profit growth expectations, citing challenges in the GLP-1 market as the reason for the adjustment [1] Group 1: Stock Performance - The company's American Depositary Receipts (ADR) experienced a significant drop of over 20% last Tuesday, marking the largest intraday decline since 1987 [1] Group 2: Legal Actions - A group of shareholders filed a proposed class-action lawsuit in federal court in New Jersey on July 28, seeking damages for alleged securities fraud occurring between May 7 and July 28, 2025 [1] - The plaintiffs accuse Novo Nordisk of making overly optimistic statements and disseminating false and misleading information, exaggerating its growth potential while concealing significant adverse facts [1] - The lawsuit claims that the stock price collapse resulting from the lowered performance guidance led to substantial losses for shareholders [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Lockheed Martin Corporation, alleging violations of the Securities Exchange Act of 1934 due to misrepresentations regarding the company's internal controls and risk-adjusted profit booking rate [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated on behalf of investors who purchased Lockheed Martin securities between January 23, 2024, and July 21, 2025 [3]. - Defendants in the lawsuit include the company and certain senior officers, accused of making false statements about the company's internal controls [4]. Group 2: Legal Process and Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by September 26, 2025, although participation as a lead plaintiff is not required to share in any potential recovery [5]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [6].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Issues - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities, with the case pending in the U.S. District Court for the Central District of California [2]. - The company allegedly failed to disclose "adoption challenges" for its products, despite promoting strong sales figures, leading to a slowdown in LAL utilization first noted in 2024 [4]. Group 3: Stock Performance - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, resulting in a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell again by about 38%, from $12.79 to $7.95 per share [6].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between September 17, 2024, and May 26, 2025 [1]. - Defendants allegedly made positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) [2]. - Following the announcement of a clinical hold by the FDA due to a SAE, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2] Group 1: Company Overview - RxSight, Inc. specializes in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery, with its main product being the Light Adjustable Lens (LAL) [3] - The LAL can be customized post-surgery through non-invasive light treatments, utilizing a Light Delivery Device (LDD) to optimize vision based on individual patient needs [3] Group 2: Allegations and Market Impact - The lawsuit claims that RxSight failed to disclose "adoption challenges" in its products while promoting strong sales of LAL and LDD, despite experiencing a slowdown in LAL utilization first noted in 2024 [4] - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, citing a "softening" market that began in the second half of 2024, leading to a stock price decline of approximately 38%, from $26.12 to $16.21 per share [5] - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell another 38%, from $12.79 to $7.95 per share [6]